Overview

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

University of Michigan Cancer Center
University of Michigan Rogel Cancer Center

Collaborator:

VA Ann Arbor Healthcare System

Treatments:

Antibodies, Monoclonal
Nivolumab